Back

Comparison of cardiovascular outcomes between chlorthalidone and hydrochlorothiazide in hypertensive patients

31 August 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Treatment of hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Assistant Professor Subin Lim

Ewha Womans University, Seoul (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Comparing adrenalectomy and mineralocorticoid receptor antagonists in primary aldosteronism: a systematic review and meta-analysis of cardiac outcomes
Doctor F. Zoccatelli (Verona, IT)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of single-pill combination perindopril/amlodipine switched from combinations of other renin-angiotensin system inhibitors and calcium channel blockers: results from ESPRIT trial
Ms Q. Liang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Effects of intensive systolic blood pressure control in diabetic patients: a systematic review and meta-analysis comparing <120 mmHg vs. <140 mmHg targets
Doctor J. Giorgi (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Sustained control of systolic blood pressure and resting heart rate within target ranges improve cardiovascular outcomes in patients with hypertension
Professor Y. Chen (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
The comparative antihypertensive efficacy of torasemide and mineralocorticoid receptor antagonists in patients with resistant hypertension
Professor L. Mishchenko (Kyiv, UA)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of hypertension

The Event

Event poster

ESC Congress 2025

31 August 2025 12:15 CET
You may be interested in
thumbnail
Congress Session
Pharmacological management of hypertension
thumbnail
Congress Session
Late-Breaking Clinical Trials: hypertension
thumbnail
Congress Presentation
Hypertension, diabetes, and the kidney: a triple threat for adverse cardiovascular events?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources